Related Experiment Video

Updated: Aug 21, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease

Paul P Dobesh1, Zachary A Stacy, Alexander J Ansara

  • 1Division of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO 63110, USA. pdobesh@stlcop.edu

Pharmacotherapy
|November 13, 2004
PubMed

Insights

Drug-eluting stents combine mechanical and drug therapies to combat restenosis, a common complication of coronary artery interventions. This innovative approach aims to reduce intimal growth and improve patient outcomes in coronary artery disease treatment.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality and significant healthcare expenditure in the US.
  • Percutaneous coronary intervention (PCI) has improved CAD outcomes but is limited by restenosis.
  • Restenosis, characterized by intimal layer proliferation, persists despite current treatments like stents and pharmacotherapy.

Purpose of the Study:

  • To evaluate the efficacy of drug-eluting stents (DES) in preventing restenosis after PCI.
  • To explore the combined mechanical and pharmacological mechanisms underlying DES effectiveness.
  • To discuss the role of DES in managing coronary atherosclerosis.

Main Methods:

  • Review of existing literature on DES technology and clinical outcomes.
  • Analysis of preclinical and clinical studies investigating DES performance.
  • Examination of the pathophysiology of restenosis and the pharmacology of drug elution from stents.

Main Results:

  • Drug-eluting stents have demonstrated significant reduction in intimal hyperplasia and restenosis rates compared to bare-metal stents.
  • Various DES formulations show promise in preventing neointimal growth post-stent deployment.
  • Clinical data suggests improved long-term patency rates with DES use in CAD patients.

Conclusions:

  • Drug-eluting stents represent a significant advancement in interventional cardiology for preventing restenosis.
  • The combination of mechanical scaffolding and localized drug delivery offers a superior approach to managing coronary atherosclerosis.
  • Further research into DES pathophysiology and pharmacology is crucial for optimizing treatment strategies.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...